Background
Parkinson’s disease (PD) is a progressive neurodegenerative disease caused by the loss of dopaminergic neurons in the substantia nigra [
1]. PD usually occurs in individuals over 50 years of age, and its incidence and prevalence increases among individuals approximately 60 years of age and older. PD has become more common due to the rapid aging of human populations around the world [
2]. Epidemiological studies have reported that the incidence of PD is 1.5–2 times higher in men than in women, and the onset of symptoms may occur later in women due to the neuroprotective effects of estrogen [
3]. For the disease manifestations of PD, women have higher Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores, but present with dyskinesia, tremor, and PD-related complications more often than men [
4].
Because the FDA reported that eight out of ten new drugs that had been sold on the market were discontinued because they resulted in far more detrimental side effects in women, the sex perspective began to be discussed in many other fields as well [
5]. Adverse drug reactions can be caused by the physiological difference between men and women, and women can be more vulnerable to a particular drug [
6]. Because sex is often not considered an important variable in animal research with the exception of research related to features of a particular sex, such as reproduction and endocrine secretion, the overwhelming majority of experimental research uses only males and many studies do not even disclose the sex of the experimental animals. Basic research studies using cells in culture also often fail to present the sex of the organism from which the cell strain originated, but the results of such basic research has been applied generally to humans. Because medical research studies are performed primarily by male researchers [
7‐
9], the research subjects are also mostly males [
10‐
12], and there has been a tendency to be careless of females [
13], which can aggravate treatment problems related to the physiological differences between men and women. The National Institutes of Health (NIH) requires applicants to report their cell and animal inclusion plans as part of the preclinical experimental design [
14]. Therefore, studies are being performed to determine what sex differences need to be accounted for in preclinical and clinical stages, and the importance of the applying these principles is being highlighted [
15].
PD treatment options include pharmacological treatment, non-pharmacological treatment, surgical therapy, and dopaminergic cell transplantation [
15]. Acupuncture has long been employed for numerous disorders, and it has been traditionally used to relieve PD-related symptoms and to delay the clinical progression of PD symptoms [
16]. We have reported that acupuncture exerts increased neuroprotective effects in regions including the substantia nigra, caudate, thalamus, and putamen in animal models of PD [
17‐
20]. Acupuncture was also found to inhibit microglial activation, inflammation, and iron-related oxidative damage in PD [
21].
Sex differences have emerged recently as an important issue, but sufficient efficacy tests for sex differences in acupuncture, as in preclinical studies for drug development, have not yet been performed. It is necessary to clarify efficacy differences according to sex in order to more effectively utilize acupuncture in clinical practice. Therefore, we carried out the present study to identify whether adequate research has been conducted so far to determine the sex differences in the efficacy of acupuncture. Specifically, we analyzed past studies of acupuncture treatment conducted in animal PD models, and determined whether the body of data was sufficient to determine the effects of sex differences on the effectiveness of acupuncture treatment. This review provides the basis for establishing whether future animal model studies are necessary to determine possible sex-related differences in the efficacy of acupuncture for PD.
Methods
Search methods for the identification of studies
The search was performed without restrictions on language or year of publication. We searched Medline, EMBASE, and the Cochrane Central Register of Controlled Trials from the inception of each database through March 2015. For Korean publications, we searched three Korean medical databases (Research Information Service System, National Discovery for Science Leaders, and OASIS). For Chinese articles, we searched the China National Knowledge Infrastructure. The keywords used for the search were the following: “Parkinson’s disease” OR “Parkinson” AND “acupuncture” OR “acupoints” OR “electroacupuncture” OR “electro-acupuncture” OR “auriculotherapy” OR “auriculoacupuncture” OR “bee venom acupuncture” in each database language. The search strategy was adjusted for each database.
Inclusion/exclusion criteria
We included studies of the use of acupuncture treatment in animal PD models. Trials were excluded if the study designs did not evaluate the effectiveness of acupuncture in animal PD models, or if they reported insufficient data. No search restrictions on language or publication forms were imposed. During the first stage of selection/exclusion, titles and abstracts were analyzed, and literature that had no relevance to our study was excluded. The second stage of selection/exclusion involved analyzing the full text of particular studies, because it was impossible to determine the relevance of the studies based solely on the abstracts.
Two reviewers (LSH and KJY) independently reviewed the data extracted from each article using a standardized data extraction form and reached consensus on all items. The extracted data included the type of animal PD models, the sex of the animal PD models, the methods used to induce PD, the types of acupuncture, the acupuncture points, and the effectiveness of the treatment.
Discussion
We analyzed sex differences among previous studies that used animal PD models of acupuncture treatment. A total of 810 potentially relevant articles were identified, 57 of which met our inclusion criteria. C57/BL6 mice were the most frequently used (42 %) animal PD models. Most of the studies evaluating the effectiveness of acupuncture treatment for PD were performed using only male animals (67 %); only one study (2 %) was performed using female animals.
Many studies have inadvertently excluded females from animal studies of acupuncture treatment for PD. Kang et al. suggested that acupuncture could be used as a neuroprotective intervention for inhibiting microglial activation and inflammatory events in the MPTP-induced male PD model [
52]. Yu et al. showed that acupuncture treatment displays antioxidative and/or neuroprotective properties in the 6-OHDA lesioned male rat PD models [
3]. Although a few studies were performed using a male/female mix, they could not combine and compare the results from male versus female animals. Only one report used female animals, in which was a study in which different frequencies of chronic EA stimulation were tested in a partially-lesioned female rat model of PD induced by transection of the MFB. This study suggested that long-term high frequency EA is effective in halting the degeneration of dopaminergic neurons in the substantia nigra (SN). Because the studies of male PD models generated using MFB transection are nonexistent, we could not compare the sex differences in this model. Taken together, there is currently insufficient evidence from past studies to determine whether there are sex differences in the effectiveness of acupuncture for animal PD models. In the future, studies should be performed using a male/female mix to minimize performance bias, and ideally should include a comparison of the sex differences.
Animal studies have often focused primarily on males. For the most part, examination of the differences between males and females has been disregarded in biomedical research, leaving gaps in our knowledge [
42]. Recently, new drugs have been developed without considering the physiological characteristics of females or sex differences. Women have therefore been frequently exposed to dangerous side effects because the experimental studies and clinical trials had mainly used male subjects [
70]. The lack of female participation in drug-development studies affects males as well as females; when side effects not seen in males during the drug safety checks appear in females, the approval of the drugs is delayed, and male patients waiting for the drugs consequently suffer. The NIH requires applicants to report their cell and animal inclusion plans as part of the preclinical experimental design. Despite this NIH policy, numerous scientific publications continue to neglect sex-based considerations and analyses in preclinical and clinical research. A stronger commitment to reporting sex-specific results will strengthen the evidence base [
13]. Fortunately, sex differences are increasingly recognized as factors that influence the incidence and disease manifestations of all diseases, including neurodegenerative disorders.
Some gender differences have been documented for PD [
3,
4]. Paven et al. suggested gender differences in the epidemiology, clinical features, treatment outcomes (medical and surgical/deep brain stimulation), and social impact among all available PD studies [
4]. Wooten et al. performed a meta-analysis of the differences in the incidence of PD between men and women [
3]. Smith et al. summarized evidence that estrogen and selective estrogen receptor modulators are neuroprotective in PD, and reviewed sex differences in basal ganglia function and dopaminergic pathways [
71,
72]. Consistent with these past studies, if acupuncture research involved both males and females, additional studies of acupuncture for PD would provide a more robust conclusion about sex differences in this treatment.
Review limitations and future areas of research
A number of gaps in the reviewed literature were identified in relation to study quality and findings. Study quality could be improved by using female animal models because they reflect the physiological characteristics of both males and females to fully evaluate the effectiveness and safety of the treatment for each sex, which is largely missing in the literature so far.
Conclusions
The results of our review suggest that acupuncture is an effective treatment for animal PD models, but there is insufficient evidence to determine whether sex differences exist in response to this treatment. Future studies should examine the effects of acupuncture in animal PD models of both sexes, to reflect the physiological characteristics of females as well as males, and to fully evaluate the effect and safety of this treatment.
Acknowledgements
We would like to thank Jong-Yeop Kim for his assistance with the collection of data used for this study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.